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Abstract 
Cigarette smoking is the leading cause of lung cancer and chronic obstructive pulmonary disease (COPD). 
Many of the detrimental effects of cigarette smoke have been attributed to the development of DNA damage, 
either directly from chemicals contained in cigarette smoke or as a product of cigarette smoke-induced 
inflammation and oxidative stress. In this review, we discuss the environmental, epidemiological, and 
physiological links between COPD and lung cancer and the likely role of DNA damage and repair in COPD and 
lung cancer development. We explore alterations in DNA damage repair by DNA repair proteins and pathways. 
We discuss emerging data supporting a key role for the DNA repair protein, xeroderma pigmentosum group C 
(XPC), in cigarette smoke-induced COPD and early lung cancer development. Understanding the interplay 
between cigarette smoke, DNA damage repair, COPD, and lung cancer may lead to prognostic tools and new, 
potentially targetable, pathways for lung cancer prevention and treatment. 
Keywords: emphysema, cigarette smoke, mutations, oxidative stress, nucleotide excision repair 
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COPD and Lung Cancer: Links in Exposure and Epidemiology 
Chronic obstructive pulmonary disease (COPD) and lung cancer represent a large burden of lung 
disease worldwide. Lung cancer is the leading cause of cancer-related mortality, estimated to cause more than 
1.6 million deaths worldwide per year [1]. COPD is an even larger burden, as it is currently the third-leading 
cause of death worldwide, causing more than 3.2 million deaths in 2015 [2, 3]. On the surface, COPD and lung 
cancer are very different diseases. COPD is characterized by two main findings: irreversible expiratory air flow 
limitations caused by narrowing and inflammation of the small airways (obstructive bronchiolitis) and 
progressive destruction and enlargement of distal lung tissue (emphysema). These findings are often 
accompanied by an altered damage response to cigarette smoke, leading to an increase in apoptosis, altered 
autophagy, and premature senescence [4]. Alternatively, lung cancer is characterized by unchecked cellular 
proliferation and alterations in the normal response to DNA damage, most characteristically through anti-
apoptotic and pro-proliferative processes [5]. However, many studies support a clear connection between 
these two seemingly disparate diseases. The most common causative exposure leading to each of these 
diseases is tobacco smoke inhalation, particularly through cigarette smoking. However, only a minority of 
smokers develop COPD or emphysema (10–15%), indicating that other epigenetic, genetic, and/or 
environmental factors play a crucial role in their development [6]. While some have speculated that the 
development of COPD or lung cancer may simply represent two extreme end-results of cigarette smoke 
exposure, numerous other studies have suggested that COPD and lung cancer share many commonalities. 
Cross-sectional and epidemiological studies have identified COPD as a risk factor for lung cancer 
development, even when corrected for smoking history. Lung cancer is identified as the cause of death in a 
third of patients with mild-to-moderate COPD: a number disproportionate to the expected number with lung 
cancer based on smoking alone [7], Furthermore, bronchoscopic biopsies from approximately half of those with 
COPD (56% of men and 44% of women) show early cancerous changes in the lung epithelium, ranging from 
moderate dysplasia to carcinoma in situ [8]. COPD-associated airway obstruction, measured by both 
spirometric severity score and the decrease in forced expiratory volume in one second (FEV1), is inversely 
correlated with lung cancer risk. The NHANES database reveals a 3-fold increase in lung cancer in those with 
mild COPD and a 6-fold greater risk in patients with moderate-to-severe COPD, compared to those with 
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normal spirometry results [9]. Cross-sectional analyses of smokers matched for age, gender, and smoking 
volume have shown a 4- to 6-fold increased risk of lung cancer in patients with COPD, with decreases in FEV1 
being inversely proportional to increases in lung cancer risk [10, 11]. This relationship between COPD severity 
and lung cancer risk is further supported by the recent prospective study of spirometric data by the NLST-
ACRIN cohort, showing a linear increase in lung cancer diagnosis with increasing COPD severity, as 
measured by the GOLD staging system [12]. Carriers for alpha-1 antitrypsin disease, a hereditary cause of 
COPD, have approximately twice the risk of lung cancer compared to matched controls, even when adjusted 
for smoking history and age, thus supporting a smoking-independent link between COPD and lung cancer [13]. 
In addition to physiological changes, structural changes seen in COPD also appear to increase the risk of lung 
cancer, with increased alveolar destruction, observed on computed tomography scans, correlating with a 
higher risk of lung cancer [14–16].  
Familial Aggregation, Genetics, and Epigenetics 
Smoking-induced lung cancer and COPD are both characterized by familial aggregation. A family 
history of lung cancer confers approximately 2.5-fold increased risk of lung cancer development, when 
corrected for smoking history [17]. A number of studies have investigated candidate genetic markers and gene 
variations, which seem to confer an increased susceptibility to lung cancer and COPD. Among these are genes 
involved in cellular metabolism, damage response mechanisms, immune regulation, protease/anti-protease 
activity, and DNA repair [6].  More recent studies have highlighted potentially important roles of epigenetic 
changes, such as DNA methylation, microRNA expression, and histone acetylation, in the link between 
cigarette smoke, COPD, and lung cancer development [18]. While these links have been described, care 
should be taken to not apply this uniformly across both diseases. For instance, there may be differences in 
lung cancer susceptibility based on the predominant COPD features (emphysema or bronchiolitis), which vary 
from person to person and are characterized by different pathological and physiological findings. Similarly, 
differences in exposure, cellular mechanisms, and the local environment, lead to differential development of 
histological sub-types of lung cancer [19], which may not be uniformly linked to COPD risk or development. 
Finally, both lung cancer and COPD are diseases characterized not only by chronic cigarette smoke exposure, 
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but also by advanced age. Cellular and environmental characteristics of advanced lung aging, such as cellular 
senescence, impaired telomere maintenance, altered autophagy, proteasome imbalance, chronic 
inflammation, and impaired oxidant defense, may provide further clues into the COPD-lung cancer overlap [20, 
21]. These and additional epidemiological, genetic, and mechanistic links have been covered in other excellent 
reviews [6, 18].  
Cigarette Smoke, Pulmonary Inflammation and DNA Damage 
COPD and lung cancer are both characterized by an altered local immune response. An increase in 
lung macrophages and neutrophils, which is a hallmark of COPD, causes the release of proteases, cytokines 
and oxidative stress, leading to the destruction of the extracellular matrix, loss of cellular integrity within the 
alveoli and epithelium, and cell death [4]. Increased inflammation is also observed in lung cancer and the 
relationship between lung cancer and the surrounding inflammation is crucial to lung cancer development. This 
inflammation is believed to initially inhibit or limit cancer growth, but then adaptive responses of malignant cells 
and the surrounding matrix cells lead to an environment in which this inflammation actually serves as a driver 
of cancer growth and metastasis [5]. 
Endogenous sources of DNA damage, such as those caused by byproducts of normal cellular 
metabolism, can cause up to 105 DNA lesions per cell per day, and exposure to carcinogens such as cigarette 
smoke further increases that number [22]. Cigarette smoking causes a wide variety of DNA adducts, which can 
be found in cancer cells as well as in adjacent “normal” cells in the lungs. These DNA adducts increase with 
the number of cigarettes smoked (Figure 1). In smokers, non-oxidized DNA lesions number as high as 34 
adducts per 108 nucleotides, which is more than 10 times the number of lesions found in the DNA of non-
smokers. The number of small modified DNA bases, such as etheno-DNA adducts and oxidized bases, may be 
even higher [23–25]. Smoking-induced lung cancers are characterized by extreme genomic instability [26, 27]. 
DNA lesions cause differential activation of DNA damage repair processes depending on the amount and type 
of DNA damage. This can lead to a number of physiologic outcomes, including activation of DNA repair 
processes with subsequent repair of the DNA lesions or apoptosis, cell senescence, cell cycle alterations, 
and/or altered autophagy. In those cells that survive, unrepaired DNA lesions may eventually be repaired by 
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less fidelitous repair pathways, leading to deletions, mutations, and translocations, which can eventually lead 
to cancer [28, 29] (Figure 1). Indeed, the non-cancerous lungs of smokers often reveal characteristic 
mutations, clonal allelic loss, and altered methylation patterns characteristic of lung cancer [30–32]. 
Among other potential mechanisms, oxidant stress has been postulated to play an important role in the 
development of both COPD and lung cancer. Many studies have shown an increase in genomic DNA damage 
caused by cigarette smoke [33]. This is driven by an increase in free radicals caused directly by side-products 
of cigarette smoke or by an increase in inflammation within the lung. Oxidized DNA bases are increased in 
both COPD and lung cancer [34, 35]. An increase in nucleic acid oxidation has been observed in alveolar wall 
cells in COPD compared to cells from non-COPD lungs, linearly increasing with worsening histologic evidence 
of emphysema [36]. One of the most studied oxidized bases, 8-hydroxy-2-deoxyguonisine (8-OHdG), is 
increased by cigarette smoke and is elevated in both COPD and lung cancer [35–37]. Other types of DNA 
damage caused by reactive oxygen species, including oxidized bases, single strand breaks, and abasic sites, 
are increased in both diseases [34–36, 38, 39]. Other exposures associated with COPD, such as biomass, 
also lead to an increase in oxidative stress and DNA damage, but their levels appear higher in cigarette 
smoke-induced COPD [40]. However, the increase in DNA damage is unlikely to be due to cigarette smoke 
alone, as the lungs of patients with COPD have higher levels of DNA damage, including double-strand breaks, 
than the lungs of smokers and non-smokers without COPD [40, 41]. COPD patients have a higher frequency of 
somatic mutations and loss of heterozygosity and higher levels of microsatellite instability [38, 42–44]. In 
COPD patients, higher levels of oxidative DNA damage are found clustered in functionally significant 
sequences, including the hypoxic response element of the vascular endothelial growth factor (VEGF) promoter 
[45]. This suggests that oxidative DNA damage plays a role beyond random increases in DNA damage, 
leading to subsequent cell death by apoptosis.  
DNA Repair in Lung Cancer 
Altered DNA repair has long been established as a hallmark of cancer. Indeed, heterozygous mutations 
in a number of DNA repair proteins have been directly linked to hereditary forms of cancer development. Most 
notably, mutations in mismatch repair genes (including MLH1, MSH2, MSH6, and PMS2) are seen in 
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hereditary nonpolyposis colorectal cancer and mutations in homologous recombination genes (BRCA1 and 
BRCA2) are seen in hereditary breast and ovarian cancers [46, 47]. The discovery of EGFR gene mutations 
associated with a minority of lung cancers in non-smokers, revolutionized the thinking of lung cancer as a 
potentially targetable malignancy [48]. In spite of these very clear examples, most lung cancers found in 
smokers are not associated with a clear heritable mutation. However, there is evidence that those with 
impaired DNA repair capacity are at an increased risk for lung cancer development and that altered DNA repair 
processes likely play an important role in the development of sporadic lung cancers [49]. 
 A number of studies have implicated altered DNA repair pathways in lung cancer development. Several 
DNA repair pathways are highly involved in the repair of cigarette smoke-induced DNA damage and many of 
them have overlapping roles. The nucleotide excision repair pathway (NER) is primarily involved in the repair 
of bulky DNA lesions that distort the DNA helical structure. The base excision repair pathway (BER) is involved 
in the repair of small base modifications, including oxidized and alkylated bases, depurination/depyrimidination 
and many single strand breaks. DNA mismatch repair (MMR) is involved in repairing errors in complementary 
strand bases (misincorporated bases) and deletions. Finally, the homologous recombination repair (HRR) and 
non-homologous end-joining (NHEJ) pathways repair the highly deleterious double-strand breaks that can 
occur as a side-effect of cigarette smoke inflammation, DNA damage, or replication stress [33, 50] (Figure 1).  
 Evaluation of the impact of DNA repair proteins on early lung cancer development is complicated by the 
heterogeneity of the disease. This includes differences in histology, poor understanding of the temporal 
development of mutations, and the findings that DNA repair protein expression and function may change 
following treatment with either chemotherapy or radiation [51, 52]. To evaluate the impact of DNA repair on 
early lung cancer development, DNA repair pathways have been extensively evaluated in an attempt to 
discover single nucleotide polymorphisms and expression patterns that may be predictive of lung cancer risk or 
provide a target for interventions (Table 1). A number of candidate DNA repair genes have been investigated 
to evaluate their impact on lung cancer risk. Most of these studies have had variable findings and, where an 
association has been found, only mild impacts on lung cancer risk were detected (Table 1). The variability of 
these findings may be due to many patient-related or technical factors, including differing ethnicities or other 
population variations, differential impacts on different lung cancer histologies, smoking status, and patient age. 
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More recent studies have evaluated combinations of gene polymorphisms, often taking into consideration 
smoking status, age, and ethnic group of the study population. These studies have identified some promising 
prognostic markers of lung cancer development within specific groups [48]. 
Many recent evaluations have focused on epigenetic changes in lung cancer, with DNA methylation 
and acetylation being implicated in altering DNA repair protein expression and function [32]. These 
investigations have included the MMR proteins, MLH1 and MSH2, which are altered by gene promoter 
methylation in lung cancers [53, 54]. Altered methylation of another MMR protein, MGMT, also appears to be 
linked to lung cancer [55, 56]. A number of studies have used ex vivo DNA repair and DNA repair protein 
functional assays to evaluate the risk of lung cancer development. Decreased MGMT activity has been 
observed in cultured fibroblasts from lung cancer patients, although results have been variable in other cell 
types. However, several functional polymorphisms of MGMT, identified as possible modulators of lung cancer 
risk, decrease the repair of alkylated DNA lesions in in vitro DNA cleavage assays [57]. Within the BER 
pathway, decreased glycosylase activity of both APE1 and OGG1 in human peripheral blood mononuclear 
cells (PBMCs) has been associated with an increased risk of lung cancer development (58-60). Poor repair 
activity, as measured by an integrated score of OGG1, MPG, and APE1 activity, is also strongly associated 
with increased lung cancer risk [61]. A functional polymorphism of the BER protein, NEIL2 [R257L], is 
associated with decreased in vitro BER activity, indicating that this gene variant may play a role in lung cancer 
development [62]. Interestingly, increased activity of another BER protein, MPG, has been observed in lung 
cancer patients, implying that a careful balance between DNA damage and repair may be needed to avoid 
cancer development [63]. A number of studies support an important role for the NER pathway in lung cancer 
development. Cleavage and host cell reactivation assays performed in human blood PBMCs, correlate 
decreased NER repair with an increased lung cancer risk [49, 60, 61, 64–69].  
Several mouse models with a predisposition to multiple solid-organ tumors, highlight an important, but 
largely generalized, role of DNA repair in early lung cancer development. Deficiencies in single BER genes 
(including Ogg1) have been associated with a mild increase in oxidative DNA damage, with further increases 
seen in combination with the knock-out of other DNA repair proteins [70]. Malignant tumors are observed with 
advanced age in Ogg1-/- mice which also have other DNA repair proteins (MUTYH and MSH2) knocked out. 
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However, these findings were not isolated to the lung, as lung, ovarian, and uterine tumors and lymphomas 
were all observed. Combined deficiencies of Ogg1 and Mth1, which is involved in MMR, results in decreased 
lung tumor development, possibly from exhaustion of the dNTP pool, suggesting the likely importance and 
complex interplay of multiple DNA repair pathways in lung cancer development [71, 72]. A specific E160D 
mutation in FEN1, which is involved in BER, has also been shown to increase lung cancer development with 
age and carcinogen exposure in mice [73]. Deficiency in the MMR protein, MGMT, leads to lung tumor 
development in mice treated with the alkylating carcinogens, N-nitroso-N-methylurea (NMU) and 
dimethylnitrosamine (DMN). However, other cancers (thymus and liver) are also observed in this model [57]. 
Within the NER pathway, lung-specific CUL4A overexpression in mice is associated with an increase in 
spontaneous lung tumors with age [74, 75]. However, individual knock-out of other NER proteins shows low 
penetrance of lung cancer development, but results in accelerated tumor development with carcinogen 
exposure. Lung cancer development also increases when the individual NER protein knock-out is combined 
with the knock-out or mutation of other proteins. Of particular interest is the NER protein, XPC, which, unlike 
other NER proteins, appears to be associated with tumor development primarily in the lung [76–78]. A number 
of other mouse models have combined deficiencies of DNA repair proteins with highly aggressive conditional 
and transgenic mouse models of lung cancer, such as those involving KRas and Trp53. Combined with these 
strong oncogenes and tumor suppressor proteins, many DNA repair proteins show an important synergistic 
role in lung cancer [79–82]. However, these results must be interpreted with caution, as oncogene-driven 
mouse models may already show altered interactions with and adaptive alterations in DNA repair processes 
[83]. The impact of other DNA repair proteins and pathways on lung cancer development has also been 
investigated (Table 1). Overall, these findings support a mechanism by which lung cancer susceptibility 
involves a complex interplay of environmental and hereditary factors and in which functional impairment of 
DNA repair pathways increases lung cancer risk. 
 
DNA Repair in COPD 
 Although the direct mechanistic link has not been fully elucidated, the requirement of altered DNA 
repair for lung cancer development and progression is well established. Less well understood is the role of 
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DNA repair in COPD development. Smoking itself increases the number of DNA lesions and smokers with 
decreased DNA repair may be at an increased risk for lung diseases, including COPD. For instance, lung 
samples of patients with COPD caused by smoking, show an increase in 8-OHdG (an oxidative stress-induced 
DNA lesion), similar to that observed in healthy smokers. However, these patients have a lower number of 
apurinic/apyrimidinic sites, an intermediate in BER, suggesting decreased BER activity in the lungs of COPD 
patients compared to healthy smokers exposed to similar amounts of cigarette smoke-induced oxidative stress 
[34, 84]. Studies have attempted to find candidate genes and single nucleotide polymorphisms responsible for 
the development of COPD with and without lung cancer. Many of these studies have focused on proteins 
involved in DNA repair (Table 1). In one such study, five genes showed a strong association with COPD. Three 
of these genes are involved in glutathione metabolism (oxidative stress regulation), one is involved in DNA 
repair (ERCC1 in NER), and one is involved in genomic and mitochondrial DNA replication (RRM1) [85]. A 
recent study reported increased DNA damage and decreased repair in PBMCs from COPD patients with 
specific variants of XRCC1, OGG1 (both involved in BER), XRCC3, and XRCC4 (both involved in double-
strand break repair through HR and NHEJ, respectively). However, these results were almost certainly 
confounded by increased cigarette use in the COPD group compared to the controls (86). Polymorphisms of 
XPC, XPA, and XRCC5 (Ku80) genes have been associated with an increased risk of COPD and have also 
been implicated in cancer development [87–91]. Specific polymorphisms of DNA repair proteins believed to 
increase COPD risk may not correlate with lung cancer risk, as seen in the analysis performed by deAndrade 
et al., and may vary by tobacco use and specific alleles analyzed [85, 92].  
Impaired DNA double-strand break repair has been implicated as a driver of COPD development. In 
particular, mutations in Ku80, a protein integral to NHEJ repair of DNA double-strand breaks and encoded by 
the COPD susceptibility gene, XRCC5, on chromosome 2q, has been implicated as a risk factor in COPD 
development in both humans and mice (88, 93). Decreased levels of Ku80 have been observed in smokers 
with COPD, who also show the highest levels of oxidative DNA damage (8-OHdG), indicating a potential link 
between cigarette smoke exposure and decreased DNA repair protein expression [34]. Mouse models lacking 
the essential NHEJ protein, Ku70 (XRCC6), develop the functional and structural changes of COPD with age 
and this is associated with an increase in apoptosis [94]. PARP-1 is involved in BER and has targeted 
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therapies available. Its activation, as measured by PAR-polymerase positivity and biotinylated-NAD 
incorporation assays, is increased in peripheral lymphocytes from COPD patients when compared to those 
from subjects without COPD [95]. Microsatellite instability, often characterized by impaired MMR function, is 
increased in lung cancer and COPD [43, 96]. Mutations of MMR proteins, including MLH1, MSH2, and MGMT, 
appear to occur late in the development of non-small cell lung cancers (NSCLC) and recent studies have 
highlighted a strong association between promoter methylation of many MMR genes and NSCLC development 
[53, 55, 97–99]. As tobacco smoking is known to alter DNA methylation, this may represent another important 
connection between DNA repair, COPD, and lung cancer development. 
XPC, COPD, and Lung Cancer 
Most of the DNA repair genes implicated as possible drivers of COPD have not been directly linked to 
lung cancer development. Loss of heterozygosity at chromosome 3p is one of the earliest genetic events in 
lung cancer development, occurring even in the histologically normal epithelium of smokers [100, 101]. Many 
genes commonly mutated in cancer are involved in apoptosis and cell cycle regulation and are located on 
chromosome 3p. These include FHIT, RASSF1A, and SEMA3B (28). Also located on chromosome 3p is the 
gene encoding the DNA repair protein, xeroderma pigmentosum group C (XPC). XPC is involved in the 
recognition and repair of bulky DNA lesions through NER and has, more recently, been implicated in the repair 
of smaller oxidative DNA lesions (such as 8-OHdG) through the BER pathway [102–105]. Findings of 
decreased XPC expression in lung adenocarcinomas of mice and humans and in immunohistochemical 
analysis of human lung squamous cell carcinomas have led to speculation that decreased XPC expression 
may play an important role in early lung cancer development [106, 107]. This is further supported by 
epidemiological studies, which have proposed a link between common XPC polymorphisms and lung cancer 
development [108–110]. Exposure of C57Bl/6 mice to 6 months of cigarette smoke leads to decreased 
expression of XPC mRNA compared to littermates exposed to ambient air, but no change in the expression of 
other measured DNA repair proteins involved in the NER and BER pathways [87]. Others have reported that 
exposure of mice to side stream smoke (up to 16 weeks) decreases expression of the DNA repair proteins, 
XPC and OGG1, and decreases NER and BER activity [111]. We have recently demonstrated an important 
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role of XPC in the prevention of emphysema-like lung disease with aging in mice exposed to chronic cigarette 
smoke [87]. Xpc-/- mice develop increased lung compliance and alveolar rarefication with age, which is further 
increased by chronic cigarette smoke exposure [87]. XPC has also been identified as important factor in 
cancer development, with its best-characterized role in protecting against UV-induced skin cancers [112]. In 
mice, XPC deficiency is associated not only with UV-induced skin cancer, but also with increased lung tumor 
development with age and pro-oxidant exposure [77, 103]. XPC deficiency was not associated with an 
increased risk of other solid organ tumors and the increase in lung tumors appears to be unique to XPC 
function, rather than the NER pathway in general, since knock-out of XPA, a protein essential to NER, does not 
lead to an increase in lung tumor development in mice [76]. We have recently found that XPC protects against 
lung adenocarcinoma development caused by cigarette smoke (“5+4 months” as per Witschi et al [113]) and 
carcinogen exposure in a gene dose-dependent manner (unpublished data). This suggests a mechanism by 
which loss of a single Xpc allele may be sufficient to increase lung cancer risk with cigarette smoke/carcinogen 
exposure, as has been suggested in skin cancers [107]. Further investigations into the specific mechanisms 
underlying this risk are ongoing. The mechanism may require impaired DNA repair, altered DNA damage 
response, and changes in lung inflammation for XPC-COPD-lung cancer development. 
Conclusions 
Great progress has been made in understanding the mechanisms underlying the development of 
COPD and lung cancer. Although COPD has clearly been identified as a risk factor for lung cancer 
development, our understanding of the mechanisms underlying this connection is incomplete. Altered functions 
of DNA repair pathways are likely to play a role in this COPD-lung cancer overlap. A greater understanding of 
the link between DNA damage, chronic inflammation, and DNA repair in COPD and lung cancer will help in risk 
prediction and the development of improved therapeutic options for these two diseases. 
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Table 1: Proposed DNA repair proteins in lung cancer and COPD/emphysema 
Pathway Candidate Proteins in Lung Cancer Candidate Proteins in COPD/emphysema 
BER Gene Polymorphisms 
    APE1*    MUTYH*  PARP1ᵻ
    APEX1ᵻ  NEIL2  POLβ 
    FEN1  NUDT1  UNG* 
    MPG  Ogg1*ᵻ  XRCC1*ᵻ
DNA Repair/Functional Assays 
   Human PBMCs 
 APE1 activity decreased 
 OGG1 glycosylase activity decreased 
 MPG activity increased in lung cancer 
    In vitro repair assays 
 NEIL2 [R257L] 
Mouse Models 
    Ogg1-/- (lung, ovarian, uterine, lymphoma – age) 
    Myh-/- (synergy with Ogg1-/-) 
    FEN1 [E160D] (lung –  age and carcinogens) 
    Nth1-/- Neil1-/- (lung, liver – age) 
    Dna2+/- (lung, liver, lymphoma – age) 
Gene Polymorphisms 
    OGG1 
    XRCC1 
DNA Repair/Functional Assays 
    PARP1 (PAR+ lymphocytes, NAD incorporation) 
NER Gene Polymorphisms 
    DDB2/XPE  ERCC5/XPG  XPA* 
    ERCC1  ERCC6/CSBᵻ      XPC*ᵻ
    ERCC2/XPD*ᵻ    GTF2H4ᵻ
    ERCC4/XPF      HR23B     
DNA Repair/Functional Assays 
  Human PBMCs 
 NER repair of BPDE decreased 
Mouse Models 
    Xpc-/- (lung – age, CS, carcinogens) 
    Xpa-/- (liver – age, liver, lung-carcinogens) 
    CUL4A overexpression (lung – age) 
    Ercc1-/- (lung – with Tp53-/-) 
Gene Polymorphisms 
    ERCC1 
    XPA* 
    XPC 
Mouse Models 
    Xpc-/- (age, CS) 
MMR Gene Polymorphisms 
    EXO1  MLH3  PCNA 
    MGMTᵻ  MSH2  PMS1 
    MBD4    MSH3 
    MLH1ᵻ   MSH5 
DNA Repair/Functional Assays 
   In vitro repair assays 
 MGMT repair decreased [various mutations] 
Mouse Models 
  Mth1-/- (increased tumors/decreased lung tumors) 
   Mgmt-/- (lung, thymus, liver – carcinogens) 
   Msh2-/- (lung – with Kras) 
HRR Gene Polymorphisms 
    BRCA2  XRCC2 
    NBS1ᵻ   XRCC3 
    RAD52 
Mouse Models 
   Nbn+/- (lung, thyroid, lymphoma, ovaries, testes) 
   Rad52-/- (decreased lung cancer – carcinogen) 
Gene Polymorphisms 
    XRCC3 
NHEJ Gene Polymorphisms 
    XRCC7/DNA-PKcs      XRCC5/Ku80 
    LIG4*ᵻ     XRCC6/Ku70 
    XRCC4*ᵻ    
DNA Repair/Functional Analysis 
Human PBMCs 
    DNA-PK activity decreased 
Gene Polymorphisms 
   XRCC5/Ku80 
Mouse Models 




   ATMᵻ  FANCG/XRCC9 
    ATR    LIG1ᵻ
Mouse Models 
    FancD2-/- (lung, liver, ovarian, mammary – age) 
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* Synergy observed with other DNA repair protein variants or functional variants. ᵻ  Risk may be altered by
cigarette smoking status. Bold indicates those proteins in which certain SNPs appear to increase lung cancer
or emphysema risk, while others decrease the risk.
Figure 1: Schematic presentation of the formation, repair, and subsequent cellular and biological effects of 
tobacco smoking-induced damage to genomic DNA. The DNA damage response elicited by unrepaired 
lesions, leading to apoptosis, autophagy, and/or senescence and low fidelity repair pathways may play an 
important role in the development of genome instability and ultimately, both COPD/emphysema and lung 
cancer. DSBs: double strand DNA breaks, NNA: 4-(methylnitrosamino)-4-(3-pyridyl)butanal, NNK: 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone, NNN: N’-nitrosonornicotine, PAH: polycyclic aromatic 
hydrocarbon, ROS: reactive oxygen species, SSBs: single strand DNA breaks. 
Downloaded for Anonymous User (n/a) at Indiana University - Ruth Lilly Medical Library from ClinicalKey.com by Elsevier on January 08, 2019.
For personal use only. No other uses without permission. Copyright ©2019. Elsevier Inc. All rights reserved.
